CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer
Jorge Franco(Southwestern Medical Center), Erik S. Knudsen(Southwestern Medical Center)
Cited by 211
Related Papers
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
|Nature Communications|2015|1.1k
Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer
|Endocrine Related Cancer|2011|299
Dual Mechanisms for the Inhibition of E2F Binding to RB by Cyclin-Dependent Kinase-Mediated RB Phosphorylation
|Molecular and Cellular Biology|1997|290
The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer
|Journal of Clinical Investigation|2006|192
Hierarchical Requirement of SWI/SNF in Retinoblastoma Tumor Suppressor-mediated Repression of Plk1
|Journal of Biological Chemistry|2004|44